Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Short-term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP-CSC): A Placebo-Controlled Clinical Trial
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2018
Episode 131: Journal Club on Follow-up for AMD and PDR Patients, Phase II and III Clinical Trials, Ophthalmology Chairs in the U.S. with Dr. M. Ali Khan
Jayanth Sridhar, MD
Member Podcasts
2018
One-Year Outcome of Intravitreal Ziv-Aflibercept Therapy For Nonresponsive Neovascular Age-Related Macular Degeneration
Jay Chhablani, MD
On Demand Cases, Courses, and Papers
2017

Category: AMD-Neovascular

See more